Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | HPN | P05981 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595197 | 1.00 | PTGS2 (0.54) | PTGS2SMN1; SMN2AKR1C3PKMNPC1 | |
| SCHEMBL5593855 | 0.86 | FAAH (0.58) | PTGS2AKR1C3CA12CA1CA9 | |
| SCHEMBL5594333 | 0.86 | FAAH (0.58) | PTGS2AKR1C3MEN1KMT2AGAA | |
| SCHEMBL5593938 | 0.86 | FAAH (0.58) | PTGS2AKR1C3CA12CA1CA9 | |
| SCHEMBL5593961 | 0.85 | MGLL (0.57) | PTGS2TGM2CA12CA1CA2 | |
| SCHEMBL4858656 | 0.84 | LMNA (0.54) | PTGS2SMN1; SMN2RAB9AALDH1A1TGM2 | |
| SCHEMBL21424948 | 0.84 | NPC1 (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1TGM2 | |
| SCHEMBL4853081 | 0.83 | PKM (0.46) | PTGS2SMN1; SMN2PKMNPC1RAB9A | |
| SCHEMBL5594417 | 0.83 | NAMPT (0.47) | ALDH1A1TGM2CA12CA9MEN1 | |
| SCHEMBL5594038 | 0.82 | TRPV4 (0.54) | PTGS2AKR1C3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365069-B2 | Pyrimidone derivatives | BEXEL PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1492774-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATION AND IMMUNOLOGICAL DISEASES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-01-05 | — | — | EP | disclosed |
| US-20040259891-A1 | Novel pyrimidon derivatives | ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) | 2004-12-23 | — | — | US | disclosed |
| US-20030225075-A1 | Novel pyrimidone derivatives | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-12-04 | — | — | US | disclosed |
| WO-2003084938-A2 | PYRIMIDONE DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATIN AND IMMUNOLOGICAL DISEASES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225075-A1 | Novel pyrimidone derivatives | TPMT, TYMP, TYMS | PTGS2 1692/4885SMN1; SMN2 2536/4885AKR1C3 1046/4885 |
| US-20040259891-A1 | Novel pyrimidon derivatives | TYMS, TPMT, TYMP | PTGS2 1957/4885SMN1; SMN2 2461/4885AKR1C3 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.